In this quarterly update, experts in infectious disease and immunology discuss key developments in COVID-19 since January 2022. In this interview, Drs. Leonard and Cassandra Calabrese highlight what we currently know regarding Omicron subvariant BA.2 and its response to available therapies. Faculty also provide updates on investigational therapies and summarize recent changes to the COVID-19 emergency use authorizations.
Click here for interview transcript